Raymond James Financial’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$220M Buy
2,427,083
+202,870
+9% +$17M 0.06% 281
2026
Q1
$178M Buy
2,224,213
+86,904
+4% +$7.16M 0.05% 314
2025
Q4
$182M Buy
2,137,309
+109,097
+5% +$8.95M 0.06% 294
2025
Q3
$158M Sell
2,028,212
-52,660
-3% -$4.11M 0.05% 336
2025
Q2
$163M Sell
2,080,872
-101,083
-5% -$7.54M 0.06% 309
2025
Q1
$158M Sell
2,181,955
-706,653
-24% -$50.6M 0.06% 299
2024
Q4
$214M Buy
+2,888,608
New +$202M 0.08% 223

Other funds holding EW

Raymond James Financial's EW Position: Q2 2026 in Review

Raymond James Financial increased its Edwards Lifesciences (EW) stake by 9.1% in Q2 2026, buying an estimated $17M and bringing the position to 2,427,083 shares worth $220M. The position accounts for 0.06% of the portfolio, ranked #281.

Raymond James Financial first reported a position in EW in Q4 2024 and has held it in 7 quarters since. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Raymond James Financial held 2,427,083 shares of Edwards Lifesciences worth $220M as of Q2 2026.
  • Raymond James Financial bought 202,870 Edwards Lifesciences shares in Q2 2026, an estimated $17M.
  • Edwards Lifesciences made up 0.06% of Raymond James Financial's portfolio in Q2 2026, its #281 holding.
  • Raymond James Financial first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.